Endologix, Inc. ( ELGX) Q4 2011 Earnings Conference Call February 22, 2012 5:00 PM ET Executives Zack Kubow – The Ruth Group Investor Relations John McDermott – President and Chief Executive Officer Bob Krist – Chief Financial Officer Analysts Duane Nash – Wedbush Securities Steven Lichtman – Oppenheimer & Company Brooks West – Piper Jaffray John Putnam – Capstone Investments Roberto Morales – Adage Capital Chris Cooley – Stephens Presentation Operator
Previous Statements by ELGX
» Endologix Management Presents at JPMorgan Global Healthcare Conference (Transcript)
» Endologix's CEO Presents at Oppenheimer 22nd Annual Healthcare Conference - Event Transcript
» Endologix's CEO Hosts Lazard Capital Markets 8th Annual Healthcare Conference Call Transcript
» Endologix's CEO Presents at Stephens Inc. Fall Investment Conference - Conference Call Transcript
Furthermore, the content of this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, February 22, 2012. Endologix undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this call.With that said, I would like to turn the call over to John McDermott. John McDermott Thanks Zack. 2011 was another productive year for Endologix. We made great strides advancing our new product pipeline, expanding our sales team and laying a foundation for the launch of Nellix and Ventana. We also continue to gain market share along the way generating 24% annual revenue growth. Fourth quarter global revenue was up 22% to a record $23.4 million, this included 26% year-over-year growth in the U.S. driven by the strength of our sales team and the successful introduction of our new AFX system. Outside the U.S. we achieved 4% year-over-year growth and are pleased with our direct sales force in Europe. Looking forward we believe we are well positioned for another year of strong growth driven by continued market penetration with AFX the expansion of our sales team in Europe and the anticipated limited introduction in Europe of Nellix and Ventana. Based upon these opportunities we anticipate full year 2012 revenue will be in the range of $102 million to $107 million representing 22% to 28% annual growth. Now I would like to spend a minute going through our growth plans in more detail. In the U.S. we experienced a positive reaction to the launch of AFX in the third quarter and saw a high level of interest on physicians. We continue to promote to clinical advantages of AFX and expect to keep driving revenue growth in 2012. We ended 2011 with 72 reps and clinical specialists and budgeted 77 by the end of this year. We’ve now got over 400 years of EVAR experience in the U.S. sales force and I think they do a great job providing clinical support to physicians.
In 2012, the majority of our incremental sales and marketing investments will be in Europe. At the end of last year we have established a 12 person team including six people that will be supporting clinical cases. The team has effectively transitioned customers from our former distributor it is now starting to add cases on their own.In January we introduced AFX in Europe at the Link meeting in Germany it had a very successful live case that generated lot of interest. Over the course of 2012 we plan to build our European team up to 25 to 30 people of which we will train 15 to 20 of them to support clinical cases. I expect to see a lot of growth in Europe over the next few years and the team is off to a very good start in 2012. In December of last year we submitted our EU regulatory (Inaudible) for Nellix and expect to receive CE mark in mid 2012. The Nellix clinical experience to date will be presented at the Charing Cross Meeting in April in London. Then in summer we are planning a limited market introduction focusing on targeted number of regional EVAR centers. We will probably stay in a limited market phase through the balance of 2012 and then look at opening it up in 2013. For Ventana, we just enrolled the final patient in our CE clinical study yesterday and expect to file our regulatory (Inaudible) in the second quarter. This positions us to potentially get CE mark for Ventana in the fall of 2012 similar to Nellix we will being with a limited roll out in selective centers with a focus on achieving positive clinical outcomes in building training centers. Turning back to the United States we are well positioned with the recent launch of AFX and advancement of our other new product initiatives. Earlier this month we announced the completion of enrollment in our PEVAR clinical trial. This randomized trial included 150 patients and requires 30 day follow up. Based on our current time line we hope to receive the percutaneous indication by the end of the year, which would position Endologix as the only EVAR company with an on-label indication for percutaneous aneurism repair. Read the rest of this transcript for free on seekingalpha.com